Quintiles Named 2014 Frost & Sullivan Asia-Pacific CRO of the Year
December 08 2014 - 11:15PM
Business Wire
Sixth Win in Eight Years Highlights Quintiles’
Market Leadership in the Region
For the sixth time in eight years, Quintiles has been named
Asia-Pacific Contract Research Organization of the Year by Frost
& Sullivan, a leading business research and consulting firm.
The award honors the CRO that scores the highest in Frost &
Sullivan’s evaluation of several performance categories, including
customer service; price/performance value; pioneering best
practices; and addressing unmet needs.
Frost & Sullivan cited Quintiles’ local market knowledge;
its Asia-Pacific capabilities that complement its global offering;
and its ability to provide solutions to meet customers’ most
pressing needs as some of the reasons why Quintiles was selected as
2014 CRO of the Year.
“I’d like to thank our 10,000 employees across Asia-Pacific for
their efforts – we owe this honor to them,” said Anand
Tharmaratnam, M.D., head of Quintiles Asia-Pacific. “We have grown
our market leadership position in the region by investing early,
developing a local talent base that is leveraged globally, and
partnering with our customers to expand in Asia-Pacific. It’s
wonderful to see the efforts of our employees and our leadership
team validated by this award.”
Rhenu Bhuller, senior vice president of Healthcare at Frost
& Sullivan, said: “Advances in technology are transforming the
global healthcare industry. We are seeing a growing focus on
healthcare innovation in Asia-Pacific, with Quintiles being one of
the leaders. Quintiles is using technology to link its globally
integrated service offerings with local market expertise to meet
local customer needs.
“This allows Quintiles to work not only with large multinational
biopharma companies in Asia-Pacific but also with emerging local
companies with regional or global aspirations, which we see as the
growth engine for the life sciences industry.”
In 2014 Quintiles has been named the Best CRO in Asia at the
BioPharma Industry Awards (winning for the third time in four
years); honored as a top employer in South Korea by the Great Place
to Work Institute; and received the SCRIP Awards Best CRO honors
(winning for fourth time in five years), among other awards.
Quintiles opened its first Asia-Pacific office (Tokyo) in 1993 and
now operates in 13 countries across Asia-Pacific.
About Quintiles
Quintiles (NYSE: Q), a Fortune 500 company, is the world’s
largest provider of biopharmaceutical development and commercial
outsourcing services. With a network of more than 32,000 employees
conducting business in approximately 100 countries, we helped
develop or commercialize all of 2013’s top-100 best-selling drugs
on the market. Quintiles applies the breadth and depth of our
service offerings along with extensive therapeutic, scientific and
analytics expertise to help our customers navigate an increasingly
complex healthcare environment as they seek to improve efficiency
and effectiveness in the delivery of better healthcare
outcomes. To learn more about Quintiles, please visit
www.quintiles.com.
Click here to subscribe to Mobile Alerts for Quintiles.
Quintiles East Asia Pte LtdJay Johnson, Media Relations,
+65.9655.6635jay.johnson@quintiles.comorKarl Deonanan, Investor
Relations,
+1.919.998.2789InvestorRelations@quintiles.comwww.quintiles.com
Qimonda AG Ads (NYSE:QI)
Historical Stock Chart
From Jun 2024 to Jul 2024
Qimonda AG Ads (NYSE:QI)
Historical Stock Chart
From Jul 2023 to Jul 2024